For research use only. CJC-1295 and Ipamorelin are research chemicals not approved by the FDA for human use. Sold exclusively for laboratory purposes. Not for human consumption.
Introduction: Growth Hormone Secretagogue Research
CJC-1295 and Ipamorelin represent two distinct classes of growth hormone-related research peptides that have been extensively co-studied in preclinical settings. CJC-1295 is a GHRH (growth hormone releasing hormone) analogue, while Ipamorelin is a selective ghrelin receptor agonist. Their complementary mechanisms have made them a frequently examined pairing in endocrine and metabolic biology research.
CJC-1295: Mechanism and Research Profile
CJC-1295 is a modified version of GHRH(1-29) with substitutions that extend its half-life significantly. The DAC (Drug Affinity Complex) version binds to endogenous albumin, providing a half-life of approximately 6–8 days in animal models. The non-DAC version (also called Mod GRF 1-29) has a shorter profile of approximately 30 minutes, making it useful for studying pulsatile GH secretion models.
Research with CJC-1295 has focused on:
- Somatotroph cell signaling in the anterior pituitary
- IGF-1 axis modulation in animal models
- Lean tissue preservation in aging-related research
- Sleep architecture studies (GH pulse patterns during slow-wave sleep)
Ipamorelin: Mechanism and Research Profile
Ipamorelin is a pentapeptide ghrelin receptor agonist (GHSR-1a) notable for its selectivity. Unlike earlier-generation GHRPs (GHRP-2, GHRP-6), Ipamorelin demonstrates minimal effect on cortisol or prolactin secretion in research models, making it a cleaner tool for isolated GH pulse studies. Its selectivity has contributed to its popularity as a research compound in endocrine biology.
Research with Ipamorelin has focused on:
- Selective GHSR-1a receptor activation studies
- GH pulse amplitude modulation
- Bone mineral density models in aging research
- Appetite regulation biology (ghrelin pathway)
Why These Two Are Studied Together
CJC-1295 and Ipamorelin work through different receptors (GHRH-R and GHSR-1a respectively) to stimulate GH release via distinct pathways. In research models, combining a GHRH analogue with a ghrelin receptor agonist produces synergistic GH pulse amplification, as the two pathways are additive rather than redundant. This makes them a logical pairing for studies examining the GH axis in greater detail than either compound alone can provide.
| Property | CJC-1295 (DAC) | Ipamorelin |
|---|---|---|
| Receptor target | GHRH-R | GHSR-1a (Ghrelin receptor) |
| Mechanism | GHRH analogue | Ghrelin receptor agonist |
| Half-life | ~6–8 days (DAC form) | ~2 hours |
| Cortisol effects in models | Minimal | Minimal |
| Primary research use | GH pulse amplitude, IGF-1 axis | Selective GH secretagogue models |
Source CJC-1295 and Ipamorelin from Iron Labs
Iron Labs supplies both CJC-1295 (DAC and non-DAC) and Ipamorelin as third-party tested, HPLC-verified research chemicals. COAs are available on each product page. All products are supplied as lyophilized powder with full documentation for research use.
Browse GH research peptides → Iron Labs Research Catalog
Regulatory Notice
CJC-1295 and Ipamorelin are not FDA-approved for any human or veterinary use. Iron Labs sells these compounds strictly as research chemicals. No therapeutic or health claims are made or implied.